Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Walking the drug regulatory tightrope

Nature Biotechnology volume 21, pages 495–498 (2003)Cite this article

Regulatory agencies are being pulled in several directions at once, and drug developers must learn to adapt swiftly to a rapidly changing landscape.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Mean times for clinical and approval phases of biopharmaceuticals over the past 20 years 7.
Figure 2: Approvals of biopharmaceuticals reviewed under standard and priority ratings from 1994 to 20027.

References

  1. Bouchie, A. FDA restructures product review centers. Nat. Biotechnol. 20, 960 (2002).

    Article  CAS  Google Scholar 

  2. Biotechnology Industry Organization CEO and Investor Conference, New York, NY, February 26–27, 2003.

  3. Dove, A. Betting on biogenerics. Nat. Biotechnol. 19, 117–120 (2001).

    Article  Google Scholar 

  4. Dove, A. Promising drug is victim of bad business. Nat. Med. 8, 199 (2002).

    Article  Google Scholar 

  5. Improving Innovation in Medical Technology: Beyond 2002 (FDA, Rockland, MD, 2002).

  6. Walsh, G. Drug approval in Europe. Nat. Biotechnol. 17, 237–240 (1999).

    Article  CAS  Google Scholar 

  7. Kaitin, K.I. (ed.). Biopharmaceutical product approval times dropped 21% since 1980s (Tufts Center for the Study of Drug Development Impact Report, 5(2), Mar/Apr, 2003).

Download references

Author information

Authors and Affiliations

  1. freelance writer working, Philadelphia, PA

    Alan Dove

Authors
  1. Alan Dove
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dove, A. Walking the drug regulatory tightrope. Nat Biotechnol 21, 495–498 (2003). https://doi.org/10.1038/nbt0503-495

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0503-495

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing